| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Chaudhuri Sarbani | Chief Commercial & Medical Affairs Officer | C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY | /s/ Martin Wilson, as attorney-in-fact for Sarbani Chaudhuri | 13 Feb 2026 | 0002064940 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RCKT | Common Stock | Award | $0 | +125,924 | +79% | $0.000000 | 285,160 | 11 Feb 2026 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RCKT | Stock Option (Right to Buy) | Award | $0 | +189,076 | $0.000000 | 189,076 | 11 Feb 2026 | Common Stock | 189,076 | $3.24 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. |
| F2 | Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. |
| F3 | This option represents a right to purchase a total of 189,076 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
Chief Commercial & Medical Affairs Officer